GLP-1 Shortage Update: What's Available Now

The GLP-1 medication shortage that began in 2022 continues to evolve, with some improvements in availability but ongoing challenges for patients and providers. This widespread shortage has created treatment gaps for millions of Americans with Type 2 diabetes and obesity, forcing both patients and healthcare providers to adapt their treatment strategies.

Understanding the current landscape is essential for anyone relying on these medications. While some improvements have emerged in late 2024, the situation remains fluid and varies significantly by location, dose strength, and specific medication. Healthcare providers are working to help patients navigate these shortages while maintaining effective treatment plans, and knowing your options can make the difference between consistent care and treatment interruptions.

Current Medication Availability Status

Ozempic shortage status varies dramatically by dose strength, with lower doses more readily available than 1mg and 2mg pens. The 0.25mg and 0.5mg starter doses are typically easier to locate, while higher maintenance doses face more severe shortages. This creates particular challenges for patients who have titrated up to higher doses for optimal glucose control.

Wegovy has transitioned from severe shortage to intermittent availability as of late 2024. Novo Nordisk has increased manufacturing capacity, resulting in more consistent supply chains for most dose strengths. However, the 2.4mg maintenance dose still experiences periodic shortages, especially in high-demand metropolitan areas.

Mounjaro maintains the most consistent supply chain among brand-name GLP-1s, with Eli Lilly's manufacturing investments paying dividends in availability. Most pharmacies report reliable stock levels across all dose strengths, making it often the most viable option for new patients. Even during the ongoing doctor shortage, Mounjaro prescriptions can typically be filled without extended delays.

Understanding the Shortage Drivers

Explosive demand growth has outpaced manufacturing capacity increases by 300-400%, creating the perfect storm for ongoing shortages. The popularity of GLP-1s for weight loss has added millions of new patients beyond the original diabetes treatment population, straining supply chains designed for a much smaller patient base.

Complex manufacturing processes for GLP-1s require 6-9 months lead time for production scaling. These medications involve sophisticated biotechnology production methods that cannot be quickly ramped up like traditional pharmaceuticals. Raw material sourcing bottlenecks affect multiple manufacturers simultaneously, creating industry-wide supply constraints.

Off-label weight loss prescribing has created unexpected demand beyond diabetes treatment, with some estimates suggesting weight loss accounts for 60-70% of current GLP-1 prescriptions. This has forced manufacturers to reassess their production forecasts and invest heavily in expanded capacity. The primary care physician shortage has also contributed to delays in prescription management and patient monitoring.

Finding Available Medications Today

Use manufacturer shortage trackers and pharmacy inventory systems to check real-time availability before making trips to pick up prescriptions. Most major manufacturers now provide online tools showing current supply status by zip code and dose strength.

Call multiple pharmacies within a 25-mile radius as stock varies significantly by location, with independent pharmacies sometimes maintaining better inventory than large chains. Many patients have found success by establishing relationships with multiple pharmacies to increase their chances of finding available stock.

Consider 90-day fills when available to reduce refill frequency during shortage periods. Insurance plans often allow extended fills for maintenance medications, providing better continuity of care. Work with specialty pharmacies that often maintain better GLP-1 inventory than retail chains, as they typically have more robust supply chain relationships with manufacturers.

Alternative Treatment Options

Compounded semaglutide from 503B facilities offers FDA-regulated alternatives during shortage periods, though patients should verify the legitimacy of compounding pharmacies before use. These facilities can legally compound medications during FDA-declared shortages, providing access when brand-name versions are unavailable.

Other GLP-1 medications like dulaglutide (Trulicity) may be available when semaglutide isn't, offering similar glucose control benefits with weekly injection schedules. Liraglutide (Victoza) requires daily injections but often maintains better availability than newer GLP-1s.

Combination therapies pairing available medications can maintain glucose control when preferred single agents are unavailable. Healthcare providers may recommend combining traditional diabetes medications with whatever GLP-1 options are accessible. Oral alternatives like Rybelsus provide similar benefits without injection supply issues, though some patients experience different side effect profiles.

Availability Comparison: GLP-1s vs Traditional Options

Traditional medications like metformin and insulin remain fully available with no supply issues, providing reliable backup options for glucose control. While these medications don't offer the weight loss benefits of GLP-1s, they ensure continuous diabetes management during shortage periods.

GLP-1s offer superior weight loss benefits but traditional options provide more reliable access and predictable pricing. Many healthcare providers now recommend combination approaches that layer GLP-1s when available with traditional medications as the foundation of treatment.

Cost considerations favor traditional medications during shortage-driven price increases, with some GLP-1s seeing 20-40% price increases in shortage conditions. Insurance coverage may also be more limited for alternative GLP-1s when preferred formulary options are unavailable.

The Bottom Line

The GLP-1 shortage landscape continues evolving, with meaningful improvements in availability compared to the crisis levels seen in 2023. While Ozempic and Wegovy still face intermittent shortages, Mounjaro has emerged as the most reliable option with consistent supply chains across most markets. Patients should work closely with their healthcare providers to identify available alternatives, consider compounded options from legitimate sources, and maintain backup treatment plans using traditional diabetes medications. The combination of increased manufacturing capacity and better supply chain management suggests continued improvement through 2025, though full resolution may take additional time. With proper planning and medical guidance, patients can maintain effective diabetes and weight management despite ongoing supply challenges.

Ready to take control of your health? Get started with Doctronic today.